DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
OʼDonnell PH. et al.
Biomarker findings and mature clinical results from KEYNOTE-052: First-line pembrolizumab (pembro) in cisplatinineligible advanced urothelial cancer (UC).
J Clin Oncol 2017;
35: 4502-4502 (suppl; abstr 4502); oral presentation (DOI: 10.1200/JCO.2017.35.15_suppl.4502, no. 15_suppl [May 2017])
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.